AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2019
Feb 21, 2019
33483_dirs_2019-02-21_e8808dab-23b0-4e96-b30a-5016a2b60ad4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2019-01-07
Reporting Person: Kishimoto Takashi Kei (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-01-07 | Common Stock | M | 36114 | $2.77 | Acquired | 36114 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-01-07 | Employee Stock Option (right to buy) | $2.77 | M | 36114 | Disposed | 2021-09-07 | Common Stock (36114.0) | Direct |
Footnotes
F1: The shares underlying the option are fully vested.
More from Cartesian Therapeutics, Inc.
Regulatory Filings
2026
May 26
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Regulatory Filings
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Regulatory Filings
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8